Table 2.
Baseline characteristics of the cohort that underwent florbetapir PET.
| Normal | Mild cognitive impairment (MCI), Amyloid PET negative | Mild cognitive impairment (MCI), Amyloid PET positive | Alzheimer’s disease (AD) | p value | |
|---|---|---|---|---|---|
| Number of subjects | 277 | 242 | 305 | 125 | |
| Age, years | 74 [5.8] | 70† [8.0] | 73 [6.8] | 75 [8.1] | < 0.001 |
| Sex, number of subjects (%) | |||||
| Male | 139 (50%) | 135 (56%) | 177 (58%) | 75 (60%) | 0.18 |
| Female | 138 (50%) | 107 (44%) | 128 (42%) | 50 (40%) | |
| Education level, years | 16.5 [2.6] | 16.2 [2.5] | 16.0† [2.9] | 15.7† [2.6] | 0.021 |
| Number (%) of subjects with an APOE ε2 allele | 34 (12%) | 31 (13%) | 6 (2%)† | 5 (4%)† | < 0.001 |
| Number (%) of subjects with an APOE ε4 allele | 74 (27%) | 53 (22%) | 202 (66%)† | 86 (69%)† | < 0.001 |
| Neutrophils, ×109/liter | 3.9 [1.2] | 3.9 [1.2] | 4.1† [1.3] | 4.4† [1.4] | < 0.001 |
| Lymphocytes, ×109/liter | 1.8 [0.52] | 1.9 [0.68] | 1.7† [0.60] | 1.7 [0.58] | 0.01 |
| Monocytes, ×109/liter | 0.41 [0.14] | 0.41 [0.14] | 0.42 [0.15] | 0.43 [0.16] | 0.85 |
| Neutrophil-to-lymphocyte ratio | 2.3 [1.0] | 2.6 [0.9] | 2.7† [1.3] | 2.8† [1.3] | < 0.001 |
| Lymphocyte-to-monocyte ratio | 4.9 [1.9] | 4.9 [2.0] | 4.5† [1.8] | 4.4† [1.8] | 0.01 |
| Baseline Alzheimer's disease assessment scale total score | 9.6 [5.1] | 12.9† [6.9] | 18.8† [9.5] | 31.1† [8.6] | < 0.001 |
Data shown are means [standard deviations]. p-values were obtained by the Kruskal–Wallis or Fisher’s Exact tests, depending on the variable type.
*p-values were obtained by the Kruskal–Wallis or Fisher’s Exact tests, depending on the variable type.
†Significantly different (p < 0.05) from the normal group, using the Wilcoxon Rank Sum Test or Fisher’s Exact test, depending on variable type.